Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2025 financial results onThursday, August 7, 2025.
Insmed management will host a conference call for investors beginning at8:00 a.m. ET on Thursday, August 7, 2025, to discuss financial results and provide a business update.
Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code 7862189. The call will also be webcast live on the Company's website at www.insmed.com.
A replay of the conference call will be accessible approximately 1 hour after its completion through August 14, 2025, by dialing(800) 770-2030 (U.S.) and (609) 800-9909 (international) and referencing access code 7862189. A webcast of the call will also be archived for 90 days under the Investor Relations section of the Company's website atwww.insmed.com.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inïeammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.comto learn more.
Contact:
Investors:
Bryan DunnVice President, Investor Relations(646) 812-4030investor.relations@insmed.com
Media:
Claire MulhearnVice President, Corporate Communications(862) 842-6819media@insmed.com
https://mma.prnewswire.com/media/2544698/Insmed_Incorporated_Logo.jpg
https://c212.net/c/img/favicon.png?sn=NY34603&sd=2025-07-24
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-second-quarter-2025-financial-results-conference-call-on-thursday-august-7-2025-302510009.html
SOURCE Insmed Incorporated
https://rt.newswire.ca/rt.gif?NewsItemId=NY34603&Transmission_Id=202507240700PR_NEWS_USPR_____NY34603&DateId=20250724